Is Gyre Therapeutics Stock a Good Investment?
Gyre Therapeutics Investment Advice | GYRE |
- Examine Gyre Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Gyre Therapeutics' leadership team and their track record. Good management can help Gyre Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Gyre Therapeutics' business and its evolving consumer preferences.
- Compare Gyre Therapeutics' performance and market position to its competitors. Analyze how Gyre Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Gyre Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Gyre Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Gyre Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Gyre Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Gyre Therapeutics Stock
Researching Gyre Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 75.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.04. Gyre Therapeutics last dividend was issued on the 12th of January 2023. The entity had 1:15 split on the 31st of October 2023.
To determine if Gyre Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Gyre Therapeutics' research are outlined below:
| Gyre Therapeutics generated a negative expected return over the last 90 days | |
| Gyre Therapeutics has high historical volatility and very poor performance | |
| Gyre Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 113.45 M. Net Loss for the year was (85.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| About 75.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Cytek Biosciences Named Overall BioTech Company of the Year i |
Gyre Therapeutics Quarterly Cash And Short Term Investments |
|
Gyre Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Gyre Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Gyre Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Gyre Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Gyre Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-04 | 2023-03-31 | -0.07 | 0.15 | 0.22 | 314 | ||
2018-03-01 | 2017-12-31 | -1.53 | -1.25 | 0.28 | 18 | ||
2023-10-26 | 2023-09-30 | -0.75 | -1.05 | -0.3 | 40 | ||
2023-08-03 | 2023-06-30 | -0.07 | -1.05 | -0.98 | 1400 | ||
2017-03-09 | 2016-12-31 | -5.63 | -4.65 | 0.98 | 17 | ||
2017-05-04 | 2017-03-31 | -6.1 | -4.57 | 1.53 | 25 | ||
2022-11-23 | 2022-09-30 | -0.1 | -2.4 | -2.3 | 2300 | ||
2020-05-11 | 2020-03-31 | -0.37 | -4.2 | -3.83 | 1035 |
Gyre Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.11 B.Market Cap |
|
Gyre Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.70) | (0.73) | |
| Return On Assets | (0.80) | (0.84) | |
| Return On Equity | 5.87 | 6.17 |
Determining Gyre Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Gyre Therapeutics is a good buy. For example, gross profit margin measures Gyre Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Gyre Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Gyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gyre Therapeutics' management manipulating its earnings.
Basic technical analysis of Gyre Stock
As of the 21st of November, Gyre Therapeutics retains the Market Risk Adjusted Performance of 0.109, risk adjusted performance of 0.0493, and Downside Deviation of 4.49. Gyre Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Gyre Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Gyre Therapeutics is priced fairly, providing market reflects its last-minute price of 11.75 per share. Given that Gyre Therapeutics has jensen alpha of 0.0325, we strongly advise you to confirm Gyre Therapeutics's regular market performance to make sure the company can sustain itself at a future point.Gyre Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gyre Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gyre Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gyre Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Epstein David M. over three months ago Acquisition by Epstein David M. of 52000 shares of Gyre Therapeutics at 9.98 subject to Rule 16b-3 | ||
Epstein David M. over three months ago Insider Trading | ||
Nussbaum Rodney L over three months ago Acquisition by Nussbaum Rodney L of 1866 shares of Gyre Therapeutics at 17.86 subject to Rule 16b-3 | ||
Usman Nassim over six months ago Disposition of 100 shares by Usman Nassim of Gyre Therapeutics at 15.63 subject to Rule 16b-3 | ||
Williams Eddie over six months ago Gyre Therapeutics exotic insider transaction detected | ||
Wu Charles C over six months ago Acquisition by Wu Charles C of 170417 shares of Gyre Therapeutics subject to Rule 16b-3 | ||
Usman Nassim over a year ago Acquisition by Usman Nassim of 341652 shares of Gyre Therapeutics subject to Rule 16b-3 |
Understand Gyre Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Gyre Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0493 | |||
| Market Risk Adjusted Performance | 0.109 | |||
| Mean Deviation | 3.34 | |||
| Semi Deviation | 4.25 | |||
| Downside Deviation | 4.49 | |||
| Coefficient Of Variation | 1837.83 | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.51 | |||
| Information Ratio | 0.0333 | |||
| Jensen Alpha | 0.0325 | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0336 | |||
| Treynor Ratio | 0.099 | |||
| Maximum Drawdown | 23.57 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 9.19 | |||
| Downside Variance | 20.19 | |||
| Semi Variance | 18.1 | |||
| Expected Short fall | (3.49) | |||
| Skewness | (0) | |||
| Kurtosis | 0.9083 |
| Risk Adjusted Performance | 0.0493 | |||
| Market Risk Adjusted Performance | 0.109 | |||
| Mean Deviation | 3.34 | |||
| Semi Deviation | 4.25 | |||
| Downside Deviation | 4.49 | |||
| Coefficient Of Variation | 1837.83 | |||
| Standard Deviation | 4.53 | |||
| Variance | 20.51 | |||
| Information Ratio | 0.0333 | |||
| Jensen Alpha | 0.0325 | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0336 | |||
| Treynor Ratio | 0.099 | |||
| Maximum Drawdown | 23.57 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 9.19 | |||
| Downside Variance | 20.19 | |||
| Semi Variance | 18.1 | |||
| Expected Short fall | (3.49) | |||
| Skewness | (0) | |||
| Kurtosis | 0.9083 |
Consider Gyre Therapeutics' intraday indicators
Gyre Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Gyre Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8556.88 | |||
| Daily Balance Of Power | (0.96) | |||
| Rate Of Daily Change | 0.91 | |||
| Day Median Price | 12.31 | |||
| Day Typical Price | 12.12 | |||
| Price Action Indicator | (1.13) | |||
| Period Momentum Indicator | (1.16) | |||
| Relative Strength Index | 60.42 |
Gyre Therapeutics Corporate Filings
| 14th of November 2024 Other Reports | ViewVerify | |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 6th of September 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
F4 | 16th of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Gyre Stock media impact
Far too much social signal, news, headlines, and media speculation about Gyre Therapeutics that are available to investors today. That information is available publicly through Gyre media outlets and privately through word of mouth or via Gyre internal channels. However, regardless of the origin, that massive amount of Gyre data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Gyre Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Gyre Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Gyre Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Gyre Therapeutics alpha.
Gyre Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Gyre Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.70) | Earnings Share (1.04) | Revenue Per Share 1.464 | Quarterly Revenue Growth (0.14) | Return On Assets 0.1018 |
The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Gyre Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.